Laura Shawver is Director at ARS Pharmaceuticals, Inc. (SPRY). They have made 2 open-market trades across 1 company since 2022, most recently 2025-04-07.
CIK 0001551891
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SPRY | SELL · 10b5-1 | 2025-04-07 | 2025-04-08 | $12.30 | $1.2M | +19.0% | +12.1% | +42.1% |
| SPRY | SELL · 10b5-1 | 2025-03-05 | 2025-03-07 | $11.21 | $560K | +9.9% | +21.0% | +26.8% |
| SPRY | SELL · 10b5-1 | 2025-02-03 | 2025-02-04 | $12.31 | $616K | -3.0% | -12.9% | +15.1% |
| SPRY | SELL · 10b5-1 | 2025-01-06 | 2025-01-07 | $11.10 | $555K | +20.8% | +14.7% | +15.0% |
| SPRY | SELL · 10b5-1 | 2024-12-02 | 2024-12-04 | $13.43 | $5.2M | -17.4% | -22.2% | -27.0% |
| SPRY | SELL · 10b5-1 | 2023-09-01 | 2023-09-05 | $7.71 | $771K | +2.4% | -43.7% | -26.5% |
| SPRY | SELL · 10b5-1 | 2023-08-03 | 2023-08-07 | $7.03 | $633K | -1.6% | +7.9% | -47.7% |
| SPRY | SELL · 10b5-1 | 2023-08-01 | 2023-08-03 | $7.12 | $784K | -0.1% | +0.4% | -49.5% |
| SPRY | SELL | 2023-07-07 | 2023-07-07 | $6.36 | $113K | +17.5% | +11.0% | -35.9% |
| SPRY | SELL | 2023-07-03 | 2023-07-06 | $6.48 | $1.2M | +10.3% | +8.1% | -37.4% |
| SPRY | SELL · 10b5-1 | 2023-06-01 | 2023-06-02 | $6.84 | $1.4M | -15.1% | -6.9% | -1.9% |
| SPRY | SELL · 10b5-1 | 2022-11-09 | 2023-05-10 | $5.24 | $1.2M | +101.1% | +46.2% | +54.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.